MedicaNova and Zhejiang Medicine Announce Asthma-focused JV

MediciNova of San Diego has formed a JV with Zhejiang Medicine that will be tasked with China commercialization of a MediciNova asthma drug, MN-221. The two companies signed a Letter of Intent regarding the JV in March. The plan is to move ahead quickly, as Zhejiang Medicine said it hoped to file an IND with the SFDA for the drug by year-end. More details.... Stock Symbols: (NSDQ: MNOV) (JSDQ: 4875) (SHA: 600216) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});